Events & Presentations

Glucotrack April 2026 Investor Presentation

Title

Download

All Access TV Interview – March 2025 – Paul V. Goode, PhD, President and CEO

Glucotrack’s CBGM Technology – January 2025 – Mark Tapsak, PhD, Vice President of Sensor Technology

First Patient Enrolled – December 2024 – Paul V. Goode, PhD, President and CEO

Does the Market Really Need Another Continuous Glucose Monitor – December 2024 – Drinda Benjamin, Vice President of Marketing

Glucotrack Overview – October 2024 – Paul V. Goode, PhD, President and CEO

Sidoti Small Cap Conference, June 2024 – Paul V. Goode, PhD, President and CEO

Sidoti Small Cap Conference, June 2024 – Paul V. Goode, PhD, President and CEO

Emerging Growth Conference, April 2024 – Mark Tapsak, PhD, VP of Sensor Technology

Emerging Growth Conference, January 2024 – Paul V. Goode, PhD, President and CEO

Press Releases

Glucotrack, Inc. Announces Pricing of $10.0 Million Public Offering

Rutherford, NJ., Nov. 13, 2024 — Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the launch of a “best efforts” public offering of approximately 7,195,000 shares of common stock (or pre-funded warrants in lieu thereof) with each share of common…

GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE

Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the 2024…

GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING

Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference Rutherford, NJ, Oct. 01, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that updated preclinical data…

JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS

Biotech veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, Sept. 03, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the appointment of…

GLUCOTRACK ANNOUNCES NEW VICE PRESIDENT OF CLINICAL OPERATIONS

Glucotrack expands leadership team with clinical trial expertise for the continuous blood glucose monitor for people with diabetes Rutherford, NJ, Aug. 27, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Sandie Martha…

Glucotrack’s Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference

Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept Rutherford, NJ, Aug. 15, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology innovator focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced new findings…

GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE

Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin Rutherford, NJ, Aug. 05, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that an emerging science…

GLUCOTRACK ANNOUNCES NEW FUNDING FOR DEVELOPMENT OF ITS CONTINUOUS BLOOD GLUCOSE MONITOR

Rutherford, NJ, July 31, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has secured $4M in funding from its leading shareholder to support the upcoming First in Human clinical trial. “This…

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS

Diabetes industry veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, June 20, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it…

GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR

Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy Rutherford, NJ, June 13, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes,…